New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 15, 2012
13:55 EDTIPXL, IPXLSummer Street's biotech research team holds analyst/industry conference call
Biotech Analyst Research Team, along with an MCRI consultant, discusses Impax Lab's IPX066 Extended Release Carbidopa-Levodopa and whether it will be approved, on an Analyst/Industry conference call to be held on October 15 at 2 pm.
News For IPXL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 2, 2016
07:36 EDTIPXLImpax receives tentative FDA approval for generic Vytorin ANDA
Impax Laboratories announced that Impax has received tentative approval from the U.S. FDA for its Abbreviated New Drug Application for the generic version of the ezetimibe and simvastatin containing tablets, in 10 mg / 10 mg, 10 mg / 20 mg, 10 mg / 40 mg and 10 mg / 80 mg strengths. "We are pleased to receive tentative approval from the FDA for our generic version of Vytorin tablets," said Fred Wilkinson, President and CEO. "We will continue to work with the FDA to gain final approval upon the expiration of the U.S. patents and associated pediatric exclusivity on April 25, 2017, and are currently planning to be among the first generic products to market."

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use